Recursion Pharmaceuticals, Inc. filed a Form 8-K on November 2, 2026, disclosing the appointment of Fred Hassan as Chair of the Board of Directors, the expansion of the Board from 9 to 10 members, and the company's third-quarter 2026 operating results.

Key Highlights

  • Board expanded: The Board of Directors increased its membership from 9 to 10, effective October 31, 2026, according to the filing.
  • New Chair appointed: Fred Hassan was appointed Chair of the Board, effective immediately upon the Board's October 31, 2026 action.
  • Class II Director: Mr. Hassan was appointed as a Class II Director, with his initial term to extend until the 2029 Annual Meeting of Stockholders.
  • Compensation terms: Mr. Hassan will receive cash and equity compensation under the Recursion Pharmaceuticals Outside Director Compensation Policy, as described in the company's proxy statement filed April 30, 2026.
  • Q3 2026 results announced: A press release reporting results of operations and financial condition for the third quarter ended September 30, 2026 was furnished as Exhibit 99.1.
  • Conference data released: The company disclosed a press release announcing data presented at the CGA-IGC conference on November 2, 2026, related to REC-4881.

Recursion Adds Fred Hassan as Chair and Expands Board to Ten Members

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported in its November 2, 2026 Form 8-K that, on October 31, 2026, the Board of Directors acted on a recommendation from its Nominating and Corporate Governance Committee to increase its membership from 9 to 10 directors. The Board simultaneously appointed Fred Hassan as Chair of the Board, effective immediately, according to the filing.

The filing states that Mr. Hassan was designated a Class II Director, with an initial term running through the 2029 Annual Meeting of Stockholders. The filing noted that he has not yet been appointed to any committee of the Board. As a non-employee director, Mr. Hassan will receive compensation under the company's Outside Director Compensation Policy, described in the definitive proxy statement on Schedule 14A filed with the SEC on April 30, 2026, and will enter into the company's standard form indemnification agreement for officers and directors.

The filing further states that "there are no transactions in which Mr. Hassan has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K and there are no arrangements or understandings between Mr. Hassan and any other person pursuant to which he was selected as a director of the Company." Separately, the company disclosed Q3 2026 financial results via press release (Exhibit 99.1), an earnings call presentation dated November 3, 2026 (Exhibit 99.4), and data presented at the CGA-IGC conference concerning REC-4881 (Exhibit 99.3). The filing was signed by Ben Taylor, Chief Financial Officer. The company noted that its statements include forward-looking statements subject to risks described in its regulatory filings, and it undertakes no obligation to update them except as required by applicable law.

What Was Disclosed

Recursion Pharmaceuticals filed an 8-K on November 2, 2026, disclosing Fred Hassan's appointment as Board Chair and Class II Director effective October 31, 2026, the expansion of the Board from 9 to 10 members, Q3 2026 financial results, REC-4881 conference data, and an upcoming earnings call presentation.